Announcements Trials
Browse Landscape

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 4Observational 2

Sponsor

Conditions

Myasthenia Gravis 2Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1

Interventions

Blood Specimen Collection 123Surveys and Questionnaires 82Observation 49Radiotherapy 40Surgical Procedures, Operative 34Drug Therapy 34Biopsy 31Specimen Handling 28Data Collection 27Watchful Waiting 20Interviews as Topic 20Magnetic Resonance Imaging 18Immune Checkpoint Inhibitors 17Liquid Biopsy 16Magnetic Resonance Spectroscopy 15Immunotherapy 15Standard of Care 13pembrolizumab 12Tomography, X-Ray Computed 12Ultrasonography 11trastuzumab deruxtecan 10lenvatinib 10Radiosurgery 10Nivolumab 10Neoadjuvant Therapy 10Carboplatin 10Tissue Banks 9Restraint, Physical 9Radiation 9Endoscopy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Observational × efgartigimod alfa × Clear all
NCT06298565 2026-02-17

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

argenx

Recruiting
680 enrolled

Myasthenia Gravis

NCT06299748 2026-02-17

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

argenx

Recruiting
279 enrolled

Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡